{
    "clinical_study": {
        "@rank": "119362", 
        "arm_group": {
            "arm_group_label": "Fesoterodine (Toviaz)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to collect effectiveness and safety information of fesoterodine\n      related to their appropriate use in daily practice."
        }, 
        "brief_title": "Drug Use Investigation for Toviaz", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Overactive Bladder (OAB)", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder, Overactive"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients prescribed fesoterodine (Toviaz).\n\n        Exclusion Criteria:\n\n          -  There are no exclustion criteria"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients prescribed fesoterodine (Toviaz) by investigators involved in protocol A0221096."
            }
        }, 
        "enrollment": {
            "#text": "2000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01936870", 
            "org_study_id": "A0221096"
        }, 
        "intervention": {
            "arm_group_label": "Fesoterodine (Toviaz)", 
            "description": "Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.", 
            "intervention_name": "Fesoterodine (Toviaz)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Toviaz", 
            "Fesoterodine", 
            "Post marketing surveillance", 
            "Japanese", 
            "Overactive Bladder", 
            "OAB", 
            "Good post marketing practice", 
            "Regulatory Post Marketing Commitment Plan"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0221096&StudyName=Drug%20Use%20Investigation%20for%20Toviaz%20"
        }, 
        "number_of_groups": "1", 
        "official_title": "Drug Use Investigation for Toviaz", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The CGI-C scale measures a physician's global impression of a participant's clinical condition at final visit in terms of change relative to the start of treatment (CGI-C). At final visit, the participants CGI-C will be categorized into a three point scale as: improvement: CGI response of very much improved, much improved or minimally improved; no change: CGI response of no change; worsening: CGI response of very much worse, much worse or minimally worse", 
            "measure": "Number of Participants with Change from Baseline in Clinical Global Impression of Clinical Condition (CGI-C)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01936870"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}